Kirk Chester joins medac Pharma as lead for newest oncology product

medac Pharma has appointed Kirk Chester as National Account Manager for the organisation’s newest hepatic oncology product, CHEMOSAT®.

Kirk brings with him 18 years’ experience in the pharmaceutical industry and his extensive knowledge of both secondary and primary care will be key to medac’s continued growth plans for its portfolio of oncology products.  Having previously worked for Novartis, Teva and GSK, Kirk has worked within many healthcare sectors including oncology, ophthalmology, men’s health and urology and is delighted to join medac Pharma to promote a product that can help people with inoperable liver cancer.

Managing Director of Stirling based medac Pharma, Alastair McMurray, comments: “We are delighted that Kirk has joined the company and his appointment will be pivotal in driving the company’s growth as we strive to be a global player in the field of oncology.”

  • British Association of Dermatology (BAD) Annual Conference

    02 – 04 July 2019
    ACC, Liverpool
    Dermatology

  • British Oncology Pharmacy Association (BOPA) annual conference

    10 – 13 October 2019
    Novotel London West, London
    Oncology

  • British Society for Paediatric and Adolescent Rheumatology (BSPAR) Conference

    Date TBC
    Venue TBC
    Rheumatology

  • NMIBC Workshops: Intravesical therapies – An update on theory and practice

    Register your interest.